SCHEMBL1436063

SCHEMBL1436063

CCOC(=O)c1ccoc1CCl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.51
MAPT P10636 2/20 0.51
HSD17B10 Q99714 2/20 0.51
TSHR P16473 2/20 0.50
TP53 P04637 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
CA12 O43570 4/20 0.42
CA1 P00915 4/20 0.42
CA2 P00918 4/20 0.42
CA7 P43166 4/20 0.42
CA9 Q16790 4/20 0.42
CA14 Q9ULX7 4/20 0.42
PKM P14618 2/20 0.42
MAOB P27338 1/20 0.42
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
CYP4F2 P78329 1/20 0.41
CYP4A11 Q02928 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8635719 0.86 ALDH1A1 (0.53) ALDH1A1MAPTHSD17B10TSHRTP53
SCHEMBL6977127 0.83 ALDH1A1 (0.51) ALDH1A1MAPTHSD17B10TSHRTP53
SCHEMBL3823759 0.83 HSD17B10 (0.44) ALDH1A1MAPTHSD17B10TSHRTP53
SCHEMBL28422770 0.82 TSHR (0.53) ALDH1A1MAPTHSD17B10TSHRTP53
SCHEMBL21132539 0.82 ALDH1A1 (0.50) ALDH1A1MAPTHSD17B10TSHRTP53
SCHEMBL8628117 0.79 TSHR (0.53) ALDH1A1MAPTHSD17B10TSHRTP53
SCHEMBL1757222 0.79 ALDH1A1 (0.60) ALDH1A1MAPTHSD17B10TSHRTP53
SCHEMBL11400583 0.78 TSHR (0.53) ALDH1A1MAPTHSD17B10TSHRNPSR1
SCHEMBL158238 0.77 TSHR (0.55) ALDH1A1MAPTHSD17B10TSHRTP53
SCHEMBL17223287 0.77 TSHR (0.55) ALDH1A1MAPTHSD17B10TSHRTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940835-B1 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS GLAXO GROUP LTD (GB) 2011-03-30 EP disclosed
US-20090131431-A1 Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors GLAXO GROUP LIMITED (GB) 2009-05-21 US disclosed
EP-1940835-A1 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS GLAXO GROUP LIMITED (GB) 2008-07-09 EP disclosed
WO-2007036733-A1 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS GLAXO GROUP LIMITED (GB) 2007-04-05 WO disclosed
US-4511720-A HYPOTENSIVE AGENTS HOFFMANN-LA ROCHE INC. (US) 1985-04-16 US disclosed
US-4355033-A TREATMENT OF HYPERTENSION HOFFMAN-LA ROCHE INC. (US) 1982-10-19 US disclosed
US-4282246-A Antidiabetic furancarboxylic and thiphenecarboxylic acids PFIZER INC. (US) 1981-08-04 US disclosed
US-4244957-A HYPOTENSIVE AGENTS HOFFMAN-LA ROCHE INC. (US) 1981-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131431-A1 Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors PDE4B, PDE3B, PDE4A ALDH1A1 1603/4885MAPT 4764/4885HSD17B10 386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.